Small Cap Healthcare Gem Announces Rs 2 Dividend & 1:1 Bonus, But Chart Hints Warn of Drop; Is The Rally Over?

Vimta Labs, a top contract research and testing company, was established in 1984 and has its headquarters in Hyderabad, India. It serves firms in the food, agro, bio/pharmaceutical, medical device, speciality chemical, and electronics industries. Vimta also offers testing and environmental inspections. After the small-cap healthcare company announced excellent Q4 results and a double bonanza of dividend and bonus shares, Vimta Labs' shares closed Tuesday's trading session 1.79% higher at Rs 1039.40 per share, with a market capitalization of Rs 2,311.06 Cr.

Vimta Labs Dividend

"We hereby inform you that the Board of Directors in their meeting held on 28.04.2025 has recommended a dividend of Rs.2/- (Rs. Two only) per share on equity shares with face value of Rs.2 each for the Financial Year 2024-25, subject to the approval of Shareholders in the ensuing Annual General Meeting," said Vimta Labs in a stock exchange filing.

Vimta Labs Bonus Shares

"We hereby inform you that the Board of Directors in their meeting held on 28.04.2025 have recommended to the shareholders for their approval, issue of bonus equity shares in the proportion of 1:1, i.e., 1 (One) bonus equity share of Rs 2/ each for every 1 (One) fully paid up equity share held as on the record date. The record date for reckoning eligible shareholders entitled to receive bonus shares will be communicated later," Vimta Labs stated in a regulatory filing.

With 2,22,34,512 equity shares of Rs 2/ each, the pre-bonus issue paid-up equity share capital was Rs 4,44,69,024 as of April 28. The post-bonus issue paid-up equity share capital is anticipated to be about Rs 8,89,38,048 with 4,44,69,024 equity shares of Rs 2/ each.

According to the corporation, the estimated date of crediting or dispatching such bonus shares is June 28, 2025.

Vimta Labs Q4 Results

Vimta Labs' net profit jumped 48.34% to Rs 18.32 crore in the March 2025 quarter from Rs 12.35 crore in the March 2024 quarter. Compared to Q4FY24, when sales were Rs 72.73 crore, they increased 29.85% to Rs 94.44 crore in Q4FY25.

EBITDA increased from Rs 26.30 crore in Q4 FY24 to Rs 34.68 crore in Q4 FY25, a 31.9% improvement. In Q4 FY25, the EBITDA margin was 36.1%, compared to 36.0% in Q4 FY24. Q4 FY25 profit before tax was Rs 25.03 crore, rising 39.5% from Q4 FY24's profit of Rs 17.94 crore.

The net profit for the entire year increased 64.20% to Rs 67.34 crore in March 2025 compared to Rs 41.01 crore in the financial year ended in March 2024. In the year ending in March 2025, sales increased 19.19% to Rs 343.98 crore, compared to Rs 288.60 crore in FY24.

Ms. Harita Vasireddi, Managing Director, Vimta Labs Limited, said "We are pleased to report strong earnings and good growth this year, driven by growth in pharmaceutical services. Our pharma business benefited from increased traction in clinical and analytical services, supported by capacity expansion and deeper client engagements. Our continued investments in talent, infrastructure, and business development are strengthening our platform for long-term value creation."

"We are excited to announce our entry into Biologics Contract R&D services, a strategic move that aligns with the future of healthcare and enhances our capabilities across the biopharma value chain. This initiative will enable Vimta to offer end-to-end support for biologics development, reinforcing our position as a trusted partner in high-quality, science-driven innovation. We remain committed to scaling our capabilities, driving innovation, and delivering long-term value for our stakeholders," he further added.

Vimta Labs Share Price Target

"Vimta Labs stock price is bearish on the Daily charts with strong resistance at 1172. A Daily close below support of 992 could lead to a target of 883 in the near term," commented A R Ramachandran, Independent Research Analyst.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.